Olpasiran
amgen
[]
ocean(a) trial shows in pts with atherosclerotic disease and lp(a) &gt; 150 nmol/l, sirna drug olpasiran well tolerated, significantly reduces lp(a), ldl-c, and apolipoproteinb #aha22 download slideset here: 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/usmuA3tKft | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W